Working… Menu

Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy (STRONG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03381729
Recruitment Status : Suspended (FDA placed AVXS-101 IT administration studies on clinical hold pending further discussions regarding pre-clinical findings.)
First Posted : December 22, 2017
Last Update Posted : June 9, 2021
Information provided by (Responsible Party):
Novartis ( Novartis Gene Therapies )